title: Cambridge Healthtech Institute Signal Transduction Conference: targets for effective therapeutics.
abstract: The Cambridge Healthtech Institute Signal Transduction Conference covered three major topics over 2 days: the discovery of new signalling targets, improved technology to dissect out signal transduction pathways and the effects of small molecules on those pathways, and progress in the discovery and development of signalling modulators. There was a particular emphasis placed on the biology of protein kinases and industry efforts to develop efficacious and safe inhibitors for this target class. Of note, kinase inhibitors for therapeutic indications other than oncology, including those directed against inflammation, allergy and metabolic disorders, have reached or have nearly completed clinical testing. Other signalling targets presented included tyrosine phosphatases, intracellular and membrane-bound channels, and G-protein-coupled receptors. This article will briefly summarise the newer technologies and signalling targets but will primarily focus on the presentations covering drug discovery and development.
authors.affiliation: Rigel Pharmaceuticals, 1180 Veterans Boulevard South, San Francisco, CA 94080, USA. bwong@rigel.com
authors.forename: Brian R
authors.initials: BR
authors.lastname: Wong
mesh_terms: D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D008404:Massachusetts; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000737:chemistry; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology; D013678:Technology, Pharmaceutical / Q000379:methods*
chemical_list: D047428:Protein Kinase Inhibitors